Moderna Expects Approximately $4 Billion In Cash Costs In 2027

What happened

Moderna expects approximately $4 billion in cash costs in 2027 and annual cash costs of about $4 billion to $4.5 billion from 2027 through 2030. It expects to end 2026 with about $9 billion in total liquidity, meaning money available, including cash, investments and unused borrowing capacity. It also extended a $1.5 billion Ares credit facility, a borrowing agreement, to 2031.

Confirmed

Global impact / market context

The projected costs indicate how much cash Moderna expects to use, while its forecast resources and extended borrowing agreement may provide funding for operations. If costs exceed expectations or available funding falls short, the company could need to cut spending or seek additional financing, affecting plans for its product launch.

Analyst inference

Moderna also said it is preparing for a broader Mflusiva commercial launch during the 2027–2028 respiratory season, following expected U.S. and Canadian approvals in 2026. That launch could create sales, but the article gives no revenue forecast or details on approval likelihood.

Analyst inference

What to watch

1. Compare Moderna’s reported 2026 liquidity, meaning money available, with its $9 billion expectation; the figure includes unused borrowing capacity as well as cash and investments. Analyst inference
2. Watch for U.S. and Canadian approvals of Mflusiva in 2026, which Moderna says would precede preparation for a broader commercial launch during the 2027–2028 respiratory season. Confirmed
3. Compare future reported cash costs with the projected $4 billion to $4.5 billion annual range through 2030 to judge whether funding needs may differ from expectations. Analyst inference

Evidence

• Original source link unavailable